Overview

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, administered as separate subcutaneous (SC) injections, in obese and overweight subjects.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Islet Amyloid Polypeptide
Pramlintide